Monday, 31 August 2026European Markets

TARGOVAX Stock Bearish Momentum With A 29% Fall In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of TARGOVAX (Oslo Børs Benchmark Index_GI: TRVX.OL) dropped by a staggering 29.92% in 21 sessions from kr0.9 to kr0.63 at 10:39 EST on Wednesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is dropping 0.26% to kr1,173.42, after two sequential sessions in a row of gains.

TARGOVAX's last close was kr0.64, 67.4% under its 52-week high of kr1.96.

About TARGOVAX

Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.

Earnings Per Share

As for profitability, TARGOVAX has a trailing twelve months EPS of kr-1.402.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -32.59%.

Volume

Today's last reported volume for TARGOVAX is 169686 which is 37.83% below its average volume of 1172500.

Moving Average

TARGOVAX's value is way under its 50-day moving average of kr0.93 and way under its 200-day moving average of kr1.11.

Volatility

TARGOVAX's last week, last month's, and last quarter's current intraday variation average was a negative 3.20%, a negative 2.21%, and a positive 3.17%.

TARGOVAX's highest amplitude of average volatility was 3.59% (last week), 4.03% (last month), and 3.17% (last quarter).

More news about TARGOVAX (TRVX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com